QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=4BCCC9F0EC33103311475DC571D6E95B;jsessionid=1C7077D54E2F000BB23B3A05B78EBC7C;jsessionid=28EE42919815D9E3B3DFC1547D776CEC;jsessionid=97C3AE8A06B69C277810C28BA511C589;jsessionid=170668B68A0C25D067253E1B2403D8FE;jsessionid=DAEEA4497B627E116AE6CF435021AC48;jsessionid=923475EB6F8CA0F18075580AA58E775A (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=4BCCC9F0EC33103311475DC571D6E95B;jsessionid=1C7077D54E2F000BB23B3A05B78EBC7C;jsessionid=28EE42919815D9E3B3DFC1547D776CEC;jsessionid=97C3AE8A06B69C277810C28BA511C589;jsessionid=170668B68A0C25D067253E1B2403D8FE;jsessionid=DAEEA4497B627E116AE6CF435021AC48;jsessionid=923475EB6F8CA0F18075580AA58E775A